Cell Reprogramming-based Therapies for Autoimmune Disorders

The emergence of cell reprogramming technology provides new therapies for autoimmune diseases (AIDs) patients. Creative Bioarray is focused on developing strategies for generating patient-specific iPSCs for AIDs to provide a clinically safe regeneration platform for patient-tailored methods to AIDs research. We have the strength to provide our customers with professional and reasonable solutions.


AIDs are a heterogeneous group of immune-mediated disorders that have a lasting impact on the health of patients. The broad spectrum of autoimmune diseases includes systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, and so on. Anti-inflammatory and immunosuppressive drugs have been mainly used to treat AIDs for a long time. Currently, stem cell transplantation is commonly used in patients with AID such as hematopoietic stem cell transplantation or mesenchymal stem cell transplantation, but this therapy is limited by the shortage of available stem cells and immune rejection.

The advent of cell reprogramming techniques allows the generation of patient-specific pluripotent stem cells, which provides solutions to these problems. The unlimited proliferation ability of iPSCs can provide sufficient numbers of cells for cell therapy in AIDs patients. In addition, the use of patient-specific iPSCs minimizes the problems associated with immune rejection and ethical issues. Thus, iPSC-based therapies may allow the development of new therapies for AIDs.

Fig 1. Therapeutic potential of patient-specific iPSCs for the treatment of autoimmune disease.Fig.1 Therapeutic potential of patient-specific iPSCs for the treatment of autoimmune disease. (Son, 2016)

Development of New Therapies for AIDs based on Cell Reprogramming

Cell Reprogramming-based Therapies for Autoimmune Disorders

The iPSC technology provides a safe clinical treatment option for AIDs, as well as a suitable model for studying these diseases. Our researchers are committed to using iPSC technology to help our clients decipher the cause of disease and design and initially validate treatment options. We offer the following solutions:

  • We provide efficient solutions for our clients to generate AID-specific iPSCs. For example, we have generated integration-free specific iPSCs from patients with AIDs such as ankylosing spondylitis (AS) and systemic lupus erythematosus (SLE) through nonintegrating episomal vectors.
  • We provide solutions for our customers to develop a xeno-free culture approach for the clinical use of AID-specific iPSCs in cell transplantation therapy.
  • We provide solutions for our customers to develop improved differentiation protocols to obtain pure functional cell populations.
  • We offer characterization services for AID-specific iPSCs including assays for pluripotency, hematopoietic differentiation potential, and mesenchymal differentiation potential to provide a patient-specific and autologous platform for the therapeutic use of iPSCs.


  • Highly trained technical staffs
  • Advanced instrumentation platform
  • Short experimental cycle time
  • Data available directly for article publication

Creative Bioarray is committed to providing new technologies and tools for the development of iPSC-based new therapeutic approaches for AIDs through the development of cell reprogramming to meet the specific scientific needs of our clients. If you need professional technical support and solutions, please contact us.


  1. Son, Mi-Young.; et al. Generation and characterization of integration-free induced pluripotent stem cells from patients with autoimmune disease. Experimental & molecular medicine. 2016, e232-e232.
For Research Use Only. Not For Clinical Use.